{"id":"brivaracetam-infusion","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Somnolence"},{"rate":"8-12","effect":"Fatigue"},{"rate":"7-10","effect":"Dizziness"},{"rate":"5-8","effect":"Headache"},{"rate":"5-7","effect":"Irritability"},{"rate":"4-6","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL607400","moleculeType":"Small molecule","molecularWeight":"212.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brivaracetam is a high-affinity ligand for SV2A, a synaptic vesicle glycoprotein involved in neurotransmitter release. By binding to SV2A, it modulates synaptic transmission and reduces the propensity for seizure activity. This mechanism is similar to levetiracetam but with higher selectivity and potency for SV2A.","oneSentence":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:07.997Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of partial-onset seizures in patients with epilepsy"},{"name":"Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy"}]},"trialDetails":[{"nctId":"NCT07163572","phase":"NA","title":"Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2025-01-16","conditions":"Status Epilepticus","enrollment":152},{"nctId":"NCT03325439","phase":"PHASE3","title":"A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2019-05-07","conditions":"Electroencephalographic Neonatal Seizures","enrollment":9},{"nctId":"NCT03405714","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2018-06-01","conditions":"Epilepsy","enrollment":50},{"nctId":"NCT03021018","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2017-02-06","conditions":"Epilepsy","enrollment":46},{"nctId":"NCT03580707","phase":"PHASE2, PHASE3","title":"Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint","status":"COMPLETED","sponsor":"Rosenfeld, William E., M.D.","startDate":"2018-06-01","conditions":"Photosensitive Epilepsy","enrollment":16},{"nctId":"NCT01710670","phase":"PHASE1","title":"A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-09","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT01405508","phase":"PHASE3","title":"Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-08","conditions":"Epilepsy","enrollment":105},{"nctId":"NCT02088957","phase":"PHASE2","title":"Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures","status":"TERMINATED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2014-03","conditions":"Nonconvulsive Electrographic Seizures","enrollment":1},{"nctId":"NCT02602860","phase":"PHASE1","title":"A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2015-11","conditions":"Healthy Volunteers","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brivaracetam infusion","genericName":"Brivaracetam infusion","companyName":"UCB Pharma","companyId":"ucb-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures. Used for Adjunctive treatment of partial-onset seizures in patients with epilepsy, Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}